Search - tctmd.com

Displaying 781 - 800 of 1042

Sort: Relevancy | Date

News Daily News

Statins Seem to Reduce Alzheimer’s Disease Risk, But Race/Ethnicity and Statin Type Matter

Todd Neale

December 14, 2016

News Daily News

Al parecer las estatinas reducen el riesgo de la Enfermedad de Alzheimer, pero se deben tener en cuenta el tipo de estatina y la raza/etnicidad.

Todd Neale

December 14, 2016

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

News Daily News

PCSK9的变体与低LDL胆固醇和糖尿病风险增加相关

Michael O'Riordan

December 01, 2016

News Daily News

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Michael O'Riordan

December 01, 2016

News Daily News

Las Variantes del Gen PCSK9 se asocian a Niveles Más Bajos de Colesterol LBD y a un Mayor Riesgo de Diabetes

Michael O'Riordan

December 01, 2016

News Conference News AHA 2016

鉴于动脉粥样硬化 CVD 的上升趋势，治疗成本应该刺激政策制定者推广预防

Yael L. Maxwell

November 29, 2016

News Conference News AHA 2016

En mitad de la Marea Creciente de ECVA, los Costes del Tratamiento Deberían hacer que los Legisladores Legislasen en Materia de Prevención

Yael L. Maxwell

November 29, 2016

News Conference News AHA 2016

Amid Rising Tide of Atherosclerotic CVD, Costs of Treatment Should Spur Policy Makers to Push Prevention

Yael L. Maxwell

November 29, 2016

News Conference News AHA 2016

类药物相关的肌肉疼痛？GAUSS-3 分析称可能基因决定的

Michael O'Riordan

November 22, 2016

News Conference News AHA 2016

¿Dolor Muscular Secundario a las Estatinas? Según el Análisis GAUSS-3 Podría ser Genético

Michael O'Riordan

November 22, 2016

News Conference News AHA 2016

Statin-Associated Muscle Pain? It May Be Your Genes, Says GAUSS-3 Analysis

Michael O'Riordan

November 22, 2016

News Conference News AHA 2016

Racial Differences in How Patients Perceive CVD Risk Should Spur Rethink in Management

Yael L. Maxwell

November 16, 2016

News Conference News AHA 2016

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Michael O'Riordan

November 15, 2016

News Conference News AHA 2016

Declines in Cognition and Function Unaffected by Lowering BP, LDL Cholesterol in the Elderly: HOPE-3

Todd Neale

November 13, 2016

News Conference News AHA 2016

No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION

Shelley Wood

November 13, 2016

News Daily News

New USPSTF Guidelines Recommend Statins in ‘Appropriately Selected’ Primary-Prevention Patients

Michael O'Riordan

November 13, 2016

News Daily News

高强度他汀类药物治疗在 CVD 患者中实现超过中等强度他汀类药物的生存获益

Michael O'Riordan

November 10, 2016

News Daily News

High-Intensity Statin Therapy Offers Survival Benefit Over Moderate-Intensity Statins in CVD Patients

Michael O'Riordan

November 10, 2016

News Daily News

El Tratamiento con Estatinas de Alta Intensidad Ofrece una Mayor Supervivencia sobre las Estatinas de Intensidad Moderada en Pacientes con Enfermedad Cardiovascular

Michael O'Riordan

November 10, 2016

News Daily News

Pfizer Discontinues Investigational PCSK9 Inhibitor Bococizumab

Michael O'Riordan

November 01, 2016

Advertisement

Statins Seem to Reduce Alzheimer’s Disease Risk, But Race/Ethnicity and Statin Type Matter

Al parecer las estatinas reducen el riesgo de la Enfermedad de Alzheimer, pero se deben tener en cuenta el tipo de estatina y la raza/etnicidad.

PCSK9的变体与低LDL胆固醇和糖尿病风险增加相关

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Las Variantes del Gen PCSK9 se asocian a Niveles Más Bajos de Colesterol LBD y a un Mayor Riesgo de Diabetes

鉴于动脉粥样硬化 CVD 的上升趋势，治疗成本应该刺激政策制定者推广预防

En mitad de la Marea Creciente de ECVA, los Costes del Tratamiento Deberían hacer que los Legisladores Legislasen en Materia de Prevención

Amid Rising Tide of Atherosclerotic CVD, Costs of Treatment Should Spur Policy Makers to Push Prevention

类药物相关的肌肉疼痛？GAUSS-3 分析称可能基因决定的

¿Dolor Muscular Secundario a las Estatinas? Según el Análisis GAUSS-3 Podría ser Genético

Statin-Associated Muscle Pain? It May Be Your Genes, Says GAUSS-3 Analysis

Racial Differences in How Patients Perceive CVD Risk Should Spur Rethink in Management

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Declines in Cognition and Function Unaffected by Lowering BP, LDL Cholesterol in the Elderly: HOPE-3

No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION

New USPSTF Guidelines Recommend Statins in ‘Appropriately Selected’ Primary-Prevention Patients

高强度他汀类药物治疗在 CVD 患者中实现超过中等强度他汀类药物的生存获益

High-Intensity Statin Therapy Offers Survival Benefit Over Moderate-Intensity Statins in CVD Patients

El Tratamiento con Estatinas de Alta Intensidad Ofrece una Mayor Supervivencia sobre las Estatinas de Intensidad Moderada en Pacientes con Enfermedad Cardiovascular

Pfizer Discontinues Investigational PCSK9 Inhibitor Bococizumab

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content